Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice

Haemophilia

Volumn 18, Issue 1, 2012, Pages 139-145

  Elm, T ^a   Karpf, D M ^a   Ovlisen K ^a   Pelzer, H ^a   Ezban, M ^a   Kjalke, M ^a   Tranholm, M ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Factor VIII; Haemophilia A mice; N8; Pharmacodynamics; Pharmacokinetics

Indexed keywords

N 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; EVALUATION; HEMARTHROSIS; HEMOPHILIA; KNEE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HALF-LIFE; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; KNEE JOINT; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS;

EID: 84355162247     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02608.x     Document Type: Article

References (23)

1. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia - Recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
2. Kasper CK Hereditary plasma clotting factors disorders and their management. In: Shulman S ed. Treatment of Hemophilia, 5th edn. Montreal, Canada: Wold Federation of Hemophilia (WFH), 2008: 1-17. Accessed November 01, 2010.
3. Berntorp E. Progress in haemophilic care: ethical issues. Haemophilia 2002; 8: 435-8.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
5. Manco-Johnson MJ, Wang C, Konkle BA, Ingram-Rich R, Humes S, Soucie JM. Primary prophylaxis prevents the onset of arthropathy: longitudinal results of 603 boys with severe factor VIII deficiency analyzed through the Centers for Disease Control Universal Data Collection (CDC UDC) study. Blood 2008; 112: 1164.
6. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia: the official journal of the World Federation of Hemophilia 2010; 16: 349-59.
7. Christiansen MLS, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
8. Martinowitz U, Diuf DF, Santagostino E et al. A multi-centre, multi-national, open-label sequential trial comparing pharmacokinetics and safety of a new recombinant FVIII compound (N8) and advate in patients with haemophilia A. Haemophilia 2010; 16: 06P46.
9. Øvlisen K, Kristensen AT, Tranholm M. In vivo models of haemophilia- status on current knowledge of clinical phenotypes and therapeutic interventions. Haemophilia 2008; 14: 248-59.
10. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
11. Øvlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Haemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in haemophilia A mice. J Thromb Haemost 2008; 6: 969-75.
12. Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in hemophilia A mice. J Pharm Sci 2009; 98: 4480-4.
13. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia: the official journal of the World Federation of Hemophilia 2004; 10: 280-7.
14. Ewenstein BM, Collins P, Tarantino MD et al. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol 2004; 41: 1-16.
15. Baru M, Carmel-Goren L, Barenholz Y et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93: 1061-8.
16. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. Journal of thrombosis and haemostasis: JTH 2008; 6: 1319-26.
17. ®: A single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124-30.
18. Jesmok GJ, Cui ZH, Canivel D, Lollar P, Parker ET, Landskroner KA. Comparison of Human and Murine rFVIII in a standardized FVIII dependent bleed model in FVIII -/- mice. J Thromb Haemost 2007; 5(Suppl. 2): P-M-030.
19. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-79.
20. Pan J, Liu T, Kim JY et al. Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice. Blood 2009; 114: 2802-11.
21. Parker ET, Lollar P. A quantitative measure of the efficacy of factor VIII in hemophilia A mice. Thromb Haemost 2003; 89: 480-5.
22. Moller F, Tranholm M. A ferric chloride induced arterial injury model used as haemostatic effect model. Haemophilia 2010; 16: e216-22.
23. Valentino LA, Hakobyan N, Kazarian T, Sorensen BB, Tranholm M. Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia 2009; 15: 314-9.